Alzheimer’s Disease Diagnostics Market By Type, By Diagnostic Tests, Brain Imaging, and Others), By End User, and Geography

Alzheimer’s Disease Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Early Onset Alzheimer’s, Late-Onset Alzheimer’s, Familial Alzheimer’s Disease, and Others), By Diagnostic Tests (Genetic Testing, Neurological Exam, Mini-Mental State Exam (MMSE), Brain Imaging, and Others), By End User (Clinic, Hospital, Diagnostic Centre, and Others), and Region

Alzheimer’s Disease Diagnostics Market size was valued at US$ 4,987.1 million in 2023 and is poised to grow at a CAGR of 9.7% from 2024 to 2030. Alzheimer’s disease is a progressive brain disorder characterized by memory loss, impaired thinking, and changes in behavior. It leads to brain cell death and abnormal protein deposits. While there’s no cure, medications can manage symptoms, and support programs are available for patients and caregivers. Early detection is crucial. The increasing incidence of chronic conditions, including dementia, underscores the urgency of early diagnosis. As more people are affected by these diseases, timely identification becomes crucial for effective management and intervention. By detecting symptoms early, healthcare providers can implement targeted strategies to improve patients’ quality of life and potentially slow disease progression.

Furthermore, investments in identifying specific biomarkers have led to personalized medicine, where treatments are tailored to individual needs. For instance, the Brain-Derived Tau (BD-tau) biomarker shows promise in Alzheimer’s diagnosis. It surpasses existing blood tests, specifically targeting Alzheimer ’s-related neurodegeneration. BD-tau also aligns with cerebrospinal fluid biomarkers. However, regulatory challenges significantly affect the Alzheimer’s disease diagnostic market. Researchers and clinicians grapple with standardizing diagnostic tools, ensuring reliability, navigating ethical considerations, and achieving widespread access to biomarker-based diagnostics while managing costs remains pivotal for equitable healthcare delivery.  

Alzheimer’s Disease Diagnostics Market Key Developments:

In March 1, 2022, Quanterix, a life sciences company announced collaboration with Eli Lilly and Company, a pharmaceutical company.

  • The collaboration agreement focuses on the diagnosis, monitoring, and treatment of Alzheimer's disease.
  • The collaboration gives Eli Lilly and Company access to Quanterix's Simoa technology that is known for its ability to detect biomarkers at very low concentrations.

Alzheimers Disease Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.7%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Alzheimer’s Disease Diagnostics Market Dynamics

The rising prevalence of Alzheimer's disease, particularly among the aging population, is a significant driver for the global Alzheimer's disease diagnostics market. Early diagnosis plays a crucial role in managing the disease progression and improving patient outcomes, leading to increased demand for diagnostic tools. Technological advancements in neuroimaging techniques, such as PET and MRI scans, and the development of novel biomarkers have enhanced the accuracy and efficiency of alzheimer's diagnosis. Growing public awareness about the importance of early detection and intervention has also contributed to market growth. Additionally, increased government funding for Alzheimer's research and supportive reimbursement policies in developed countries have further stimulated the adoption of advanced diagnostic methods. However, the high cost of diagnostic procedures and limited healthcare access in developing regions remain challenges for market expansion.

Alzheimers Disease Diagnostics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 4,987.1 million

Market CAGR

9.7%

By Type

  • Early Onset Alzheimer’s
  • Late-Onset Alzheimer's
  • Familial Alzheimer’s Disease
  • Others

By Diagnostic Tests

  • Genetic Testing
  • Neurological Exam
  • Mini-Mental State Exam (MMSE)
  • Brain Imaging
  • Others

By End User

  • Clinics
  • Hospital
  • Diagnostic Centre
  • Others

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Download Free Sample Report

Frequently Asked Questions

Alzheimer’s Disease Diagnostics Market was valued at US$ 4,987.1 million in 2023 and is expected to grow at a CAGR of 9.7% from 2024 to 2030

The leading players in the global Alzheimer’s Disease Diagnostics market are Eli Lilly and Company, TauRx (Republic of Singapore), Alector LLC, Accera, Inc., Treventis Corporation, Neuro-Bio Ltd, Cognition Therapeutics Inc, Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Allergan PLC, Daiichi Sankyo Co.

Historic years considered for the market study are 2019-2022, 2023 is considered as the base year for market estimation, and Seven years forecast is presented from 2024 – 2030.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Alzheimer’s Disease Diagnostics Market Introduction 
2.1.Global Alzheimer’s Disease Diagnostics Market  - Taxonomy
2.2.Global Alzheimer’s Disease Diagnostics Market  - Definitions
2.2.1.Type 
2.2.2.Diagnostic Tests
2.2.3.End User
2.2.4.Region
3.Global Alzheimer’s Disease Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Alzheimer’s Disease Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Alzheimer’s Disease Diagnostics Market  By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Early Onset Alzheimer’s
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Late-Onset Alzheimer's
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Familial Alzheimer’s Disease
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Alzheimer’s Disease Diagnostics Market  By Diagnostic Tests, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Genetic Testing
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Neurological Exam
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Mini-Mental State Exam (MMSE)
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Brain Imaging
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Alzheimer’s Disease Diagnostics Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Clinics
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hospital
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Diagnostic Centre
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Alzheimer’s Disease Diagnostics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Alzheimer’s Disease Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Early Onset Alzheimer’s
9.1.2.Late-Onset Alzheimer's
9.1.3.Familial Alzheimer’s Disease
9.1.4.Others
9.2.  Diagnostic Tests Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Genetic Testing
9.2.2.Neurological Exam
9.2.3.Mini-Mental State Exam (MMSE)
9.2.4.Brain Imaging
9.2.5.Others
9.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Clinics
9.3.2.Hospital
9.3.3.Diagnostic Centre
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Alzheimer’s Disease Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Early Onset Alzheimer’s
10.1.2.Late-Onset Alzheimer's
10.1.3.Familial Alzheimer’s Disease
10.1.4.Others
10.2.  Diagnostic Tests Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Genetic Testing
10.2.2.Neurological Exam
10.2.3.Mini-Mental State Exam (MMSE)
10.2.4.Brain Imaging
10.2.5.Others
10.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Clinics
10.3.2.Hospital
10.3.3.Diagnostic Centre
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Alzheimer’s Disease Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Early Onset Alzheimer’s
11.1.2.Late-Onset Alzheimer's
11.1.3.Familial Alzheimer’s Disease
11.1.4.Others
11.2.  Diagnostic Tests Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Genetic Testing
11.2.2.Neurological Exam
11.2.3.Mini-Mental State Exam (MMSE)
11.2.4.Brain Imaging
11.2.5.Others
11.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Clinics
11.3.2.Hospital
11.3.3.Diagnostic Centre
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Alzheimer’s Disease Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Early Onset Alzheimer’s
12.1.2.Late-Onset Alzheimer's
12.1.3.Familial Alzheimer’s Disease
12.1.4.Others
12.2.  Diagnostic Tests Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Genetic Testing
12.2.2.Neurological Exam
12.2.3.Mini-Mental State Exam (MMSE)
12.2.4.Brain Imaging
12.2.5.Others
12.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Clinics
12.3.2.Hospital
12.3.3.Diagnostic Centre
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Alzheimer’s Disease Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Early Onset Alzheimer’s
13.1.2.Late-Onset Alzheimer's
13.1.3.Familial Alzheimer’s Disease
13.1.4.Others
13.2.  Diagnostic Tests Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Genetic Testing
13.2.2.Neurological Exam
13.2.3.Mini-Mental State Exam (MMSE)
13.2.4.Brain Imaging
13.2.5.Others
13.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Clinics
13.3.2.Hospital
13.3.3.Diagnostic Centre
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Eli Lilly and Company
14.2.2.TauRx (Republic of Singapore)
14.2.3.Alector LLC
14.2.4.Accera, Inc.
14.2.5.Treventis Corporation
14.2.6.Neuro-Bio Ltd
14.2.7.Cognition Therapeutics Inc
14.2.8.Hoffmann-La Roche
14.2.9.Novartis AG
14.2.10.Merck & Co.
14.2.11.Pfizer Inc.
14.2.12.Allergan PLC
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Eli Lilly and Company
  • TauRx (Republic of Singapore)
  • Alector LLC
  • Accera, Inc.
  • Treventis Corporation
  • Neuro-Bio Ltd
  • Cognition Therapeutics Inc
  • Hoffmann-La Roche
  • Novartis AG
  • Merck & Co.
  • Pfizer Inc.
  • Allergan PLC
  • Daiichi Sankyo Co.

Related Industry Reports